Valuation: TransMedics Group, Inc.

Capitalization 5.07B 4.36B 3.95B 3.79B 6.92B 467B 7.17B 46.43B 18.59B 223B 19.01B 18.6B 795B P/E ratio 2026 *
60.6x
P/E ratio 2027 * 40.4x
Enterprise value 5.01B 4.31B 3.91B 3.75B 6.84B 462B 7.09B 45.91B 18.38B 220B 18.8B 18.39B 786B EV / Sales 2026 *
6.8x
EV / Sales 2027 * 5.6x
Free-Float
96.82%
Yield 2026 *
-
Yield 2027 * -
1 day-0.36%
1 week+11.99%
Current month+1.65%
1 month+13.26%
3 months+6.51%
6 months+41.91%
Current year+21.38%
1 week 131.09
Extreme 131.09
151
1 month 127.5
Extreme 127.5
151
Current year 120.17
Extreme 120.171
151.85
1 year 62.07
Extreme 62.0726
156
3 years 36.42
Extreme 36.4201
177.37
5 years 10
Extreme 10
177.37
10 years 10
Extreme 10
177.37
Manager TitleAgeSince
Chief Executive Officer 57 01/08/1998
Director of Finance/CFO 55 02/12/2024
Chief Operating Officer 43 02/02/2023
Director TitleAgeSince
Director/Board Member 57 01/08/1998
Chairman 81 01/01/2011
Director/Board Member 78 01/02/2016
Change 5d. change 1-year change 3-years change Capi.($)
-0.15%+11.99%+113.66%+79.35% 5.07B
-0.91%-0.19%-0.75%-8.36% 190B
-0.30%-0.99%-10.18%+113.39% 178B
-0.45%-2.29%-0.57%-19.12% 145B
-0.30%-1.73%-30.31%+51.00% 107B
-1.75%-4.65%-23.71%-20.18% 53.73B
-1.06%+2.18%+19.39%+4.03% 49.5B
-0.42%+2.58%+11.91%+17.85% 37.74B
-1.49%-5.96%-6.27%+3.47% 36.01B
-1.03%-3.35%-2.05%-16.25% 34.06B
Average -0.83%+0.17%+7.11%+20.52% 83.65B
Weighted average by Cap. -0.72%-0.99%-5.82%+25.16%

Financials

2026 *2027 *
Net sales 736M 633M 574M 551M 1.01B 67.87B 1.04B 6.75B 2.7B 32.37B 2.76B 2.7B 116B 869M 747M 678M 650M 1.19B 80.12B 1.23B 7.97B 3.19B 38.21B 3.26B 3.19B 136B
Net income 102M 88.12M 79.96M 76.69M 140M 9.45B 145M 939M 376M 4.51B 385M 376M 16.09B 154M 132M 120M 115M 210M 14.16B 218M 1.41B 564M 6.75B 577M 564M 24.12B
Net Debt -56.97M -48.99M -44.45M -42.63M -77.86M -5.25B -80.66M -522M -209M -2.5B -214M -209M -8.95B -199M -171M -155M -149M -272M -18.35B -282M -1.82B -731M -8.75B -747M -731M -31.26B
Logo TransMedics Group, Inc.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Employees
898
Date Price Change Volume
05/03/26 147.66 $ -0.23% 701,868
03/03/26 148.00 $ +0.68% 1,535,329
02/03/26 147.00 $ +1.20% 1,091,217
27/02/26 145.26 $ +7.94% 1,227,884
26/02/26 134.57 $ +2.06% 825,089
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
147.66USD
Average target price
157.55USD
Spread / Average Target
+6.69%

Quarterly revenue - Rate of surprise